A Phase 1, Open-Label, Two-Period, Crossover Study to Evaluate the Relative Bioavailability of a New Tablet Formulation Versus the Current Capsule Formulation of PPI-668 in Healthy Adult Volunteers
Latest Information Update: 31 Jan 2014
At a glance
- Drugs Ravidasvir (Primary)
- Indications Hepatitis C
- Focus Pharmacokinetics
- Sponsors Presidio Pharmaceuticals
- 07 Jan 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 17 Nov 2013 New trial record